

1
2 **The Ohio State University Combined Consent to Participate in**
3 **Research and HIPAA Research Authorization**
4
5

Study Title: Evaluation of the efficacy of radiofrequency-based debridement vs. mechanical debridement for the treatment of articular cartilage lesions.

Principal Investigator: Christopher Kaeding, MD

Sponsor: Smith & Nephew, Inc.

6 Dr. Flanigan, a researcher helping to perform this study, has a personal financial interest in
7 Smith & Nephew, the company sponsoring this research. As a result, Dr. Flanigan could
8 financially benefit from the testing and sale of the Werewolf Coblation System. The Ohio
9 State University Institutional Review Board and the University's Conflict of Interest Advisory
10 Committee have reviewed the financial interest and determined that it poses no additional
11 significant risk to the safety of participants in the study or to the integrity of the research.
12 Any questions about this financial relationship can be answered by Dr. Christopher Kaeding
13 (614-293-8813), who has no personal financial interest in Smith & Nephew.
14

- 15 • **This is a consent form for research participation.** It contains important information
16 about this study and what to expect if you decide to participate. Please consider the
17 information carefully. Feel free to discuss the study with your friends and family and
18 to ask questions before making your decision whether or not to participate.
- 19 • **Your participation is voluntary.** You may refuse to participate in this study. If you
20 decide to take part in the study, you may leave the study at any time. No matter what
21 decision you make, there will be no penalty to you and you will not lose any of your
22 usual benefits. Your decision will not affect your future relationship with The Ohio
23 State University. If you are a student or employee at Ohio State, your decision will
24 not affect your grades or employment status.
- 25 • **You may or may not benefit as a result of participating in this study.** Also, as
26 explained below, your participation may result in unintended or harmful effects for
27 you that may be minor or may be serious depending on the nature of the research.
- 28 • **You will be provided with any new information that develops during the study**
29 **that may affect your decision whether or not to continue to participate.** If you
30 decide to participate, you will be asked to sign this form and will receive a copy of the
31 form. You are being asked to consider participating in this study for the reasons
32 explained below.
33

34 **1. Why is this study being done?**
35

36 You are being asked to participate in this research study because you require an arthroscopic
37 knee procedure for the treatment of a chondral lesion and torn meniscus. This study will

38 evaluate 2 different treatments, Mechanical Debridement (i.e., a mechanical shaver that
39 removes areas of damaged tissue) and Radiofrequency Debridement (i.e., electrical energy
40 that removes areas of damaged tissue), used to treat the chondral lesion in your knee. Your
41 torn meniscus will be treated per standard of care by your study doctor.

42

43 All of the Mechanical Debridement and Radiofrequency Debridement devices being used in
44 this study have obtained clearance by the U.S. Food and Drug Administration (FDA) for
45 commercial use and are currently being used on the market.

46

47 The study doctor would normally use any one of the methods, Mechanical Debridement or
48 Radiofrequency Debridement, to treat your knee, but right now it is not known if one of these
49 methods is better than the other. This study is being conducted to see whether Radiofrequency
50 Debridement is as effective as Mechanical Debridement in patients with knee problems such
51 as yours.

52

53 **2. How many people will take part in this study?**

54

55 A total of 82 will take part. You will be randomized at a 1:1 ratio into the Werewolf
56 Coblation wand radiofrequency debridement treatment group (electrical energy used to
57 precisely remove damaged tissue at relatively low temperatures) -or mechanical debridement
58 treatment group. This will be determined by a random process (like flipping a coin). For this
59 study you will be randomized at a 1:1 ratio, which means that you have a 50% (1 in 2) chance
60 of receiving the Werewolf Coblation wand radiofrequency debridement and 50% (1 in 2)
61 chance of receiving mechanical debridement.

62

63 **3. What will happen if I take part in this study?**

64

65 Today you will complete 4 questionnaires about your physical activity level as well as your
66 knee symptoms. You will also have repeat x-rays and MRI if your most recent imaging is
67 greater than 3 months old. Repeat x-rays are standard of care and will be billed to your
68 insurance. The repeat MRI may or may not be considered standard of care. This will be
69 determined by the physician. If your MRI is considered standard of care, it will be billed to
70 your insurance. However, if the indication for the MRI is only due to the study requirements,
71 the MRI cost will be covered by the study.

72

73 On the day of surgery, additional information regarding your procedure will be collected by a
74 member of the research staff. Your treatment group will be randomly assigned during your
75 surgery if you fulfill all criteria for the study. You will not be made aware of which
76 treatment you have received until you have completed the research study.

77

78

79 Photographs may be taken of your knee before, during, and after the surgery; however, your
80 identity will not be revealed.

81

82 You will complete additional surveys and receive a physical assessment by the surgeon at the
83 following visits after your surgery: 10 days, 6 weeks, 6 months, and 12 months. At each
84 follow-up visit, you will be asked general questions about your health. It is anticipated that
85 the additional time to complete these activities will add 20-30 minutes to your visit. Office
86 visits at 10 days and 6 weeks are considered standard of care and will be covered by the
87 global period of normal post-operative care bundled into the global surgery fee billed to your
88 insurance. Office visits at 6 months and 12 months are not considered standard of care, and
89 will be covered by the study.

90
91 You will complete weekly online surveys from 1 week to 6 weeks post-op through an online
92 data collection system called RedCap.

93
94 You will have x-rays and an MRI performed at your 12 month visit. An MRI is a magnetic
95 resonance image that will show the interior area of your knee following surgery. It is
96 anticipated that the MRI will take up to 1 hour to complete at this visit. X-rays performed at
97 this visit are anticipated to add 15-20 minutes to your visit.

98
99 The results of this study and the collection of images (X-rays and/or MRI) may be used for
100 future publications. If the results of the study are made public, information that identifies you
101 will not be used.

102

103 **4. How long will I be in the study?**

104

105 You will be in the study from today up until one year after the date of surgery.

106

107 **5. Can I stop being in the study?**

108

109 You may leave the study at any time. If you decide to stop participating in the study,
110 there will be no penalty to you, and you will not lose any benefits to which you are
111 otherwise entitled. Your decision will not affect your future relationship with The Ohio
112 State University.

113

114 **6. What risks, side effects or discomforts can I expect from being in the study?**

115

116

117 The potential medical risks associated with the study device are prolonged surgery time due to
118 device breakage or malfunction, subject burn, and/or inadvertent tissue removal.

119

120 The results of this surgery cannot be guaranteed. It is possible that the surgery will not reduce
121 the pain or disability felt before surgery. In addition, the pain or disability may be worse after
122 the surgery. It is possible that by being in the study, you can have problems and/or side effects
123 not known at this time. There is some element of this risk in all surgeries, whether or not you
124 receive the study device.

125

126 If you choose to take part in this study, you will be informed of any significant new findings
127 (either good or bad), such as changes in the risks or benefits resulting from participation in the
128 study, that might cause you to change your mind about continuing in the study. You may be
129 asked to sign a new consent form if this occurs.

130

131 Participating in more than one study may increase risks to you and may affect study results.
132 You should tell your study doctor if you are considering joining another study.

133

134 **Loss of confidentiality**

135 A risk of taking part in this study is the possibility of a loss of confidentiality. Loss of
136 confidentiality includes having your personal information shared with someone who is not on
137 the study team and was not supposed to see or know about your information. The study team
138 plans to protect your confidentiality as much as legally possible.

139

140 **Women as Study Subjects**

141 If you are a woman and are pregnant you cannot be in this study. If a woman is pregnant or
142 nursing a child when she has medication associated with surgery there may be risks to the
143 unborn baby or nursing child. If you are a woman who can become pregnant, you must have
144 a pregnancy test prior to any surgery to check that you are not pregnant.

145

146 If you think that you are pregnant during the study, you must tell the study doctor
147 immediately. If you become pregnant before the surgery, you will be removed from the study.

148

149 **MRI**

150 There are risks from an MRI if you are pregnant or have one of the following: an artificial
151 heart valve, pacemaker, metal plate, pin, or other metallic objects in your body (including
152 bullets or shrapnel). You may also become anxious or claustrophobic from lying in a tight
153 space without moving. The MRI scan does not cause any pain and does not expose you to x-
154 ray radiation. The effects of the magnetic fields in a MRI scanner have been widely studied,
155 and there are no known risks from being exposed to the magnetic fields

156

157 **Radiation Exposure from X-ray**

158 X-rays are considered to be low risk. X-rays expose you to radiation. Most radiation
159 procedures use very small amounts of radiation that are not expected to cause harm. However,
160 the exposure risk is cumulative over a lifetime, and the total should be kept as low as possible.

161

162 **7. What benefits can I expect from being in the study?**

163

164 You may not benefit directly from participating in this study. If you choose to participate
165 in the study, your condition may or may not improve. The potential benefits of the study
166 device are minimal thermal penetration and precise and efficient tissue removal. The
167 information collected in this study to determine the effectiveness of Radiofrequency
168 Debridement may benefit future patients undergoing arthroscopic knee surgery.

169

170 **8. What other choices do I have if I do not take part in the study?**

171
172 You may choose not to participate without penalty or loss of benefits to which you are
173 otherwise entitled.
174

175 **9. What are the costs of taking part in this study?**

176
177 All costs that are part of your usual medical care, such as your surgery and physical
178 therapy, will be charged to your insurance company if you have such coverage. You will be
179 responsible for all costs that are not paid by your insurance company. You should check with
180 your insurance company before you enroll in this study. If you have no health insurance you
181 will be held responsible for paying all costs of the study.

182
183 Costs which are not associated with standard treatment, such as costs of MRI required
184 specifically for this research study, will be paid for by the sponsor.

185
186 While you are in the study, you may still need to get regular medical care. You will still have
187 to pay for the costs of your regular medical care that are not a part of this study. To find out
188 more about costs, you can ask the study doctor or study personnel.

189
190 Participating in this research study may lead to additional costs to you. In some cases, it is
191 possible that your insurance company will not pay for these costs because you are taking part
192 in a research study.

193
194 **10. Will I be paid for taking part in this study?**

195
196 You will receive the following payment(s) for your participation:
197 You will be compensated \$50.00 for the pre-op, 10day, 6 week, and 12 month visits.
198 You will be compensated \$20.00 total for all your online questionnaires (1wk-6wks) and
199 \$20.00 for the 6 month visit. Payments for participation are to cover meals and
200 transportation for a maximum of \$240. You will receive check payments by mail within
201 30 business days once you have completed each study visit.

202
203 By law, payments to subjects are considered taxable income.
204

205 **11. What happens if I am injured because I took part in this study?**

206
207 If you suffer an injury from participating in this study, you should notify the researcher or
208 study doctor immediately, who will determine if you should obtain medical treatment at
209 The Ohio State University Wexner Medical Center.

210
211 The cost for this treatment will be billed to you or your medical or hospital insurance. The
212 Ohio State University has no funds set aside for the payment of health care expenses for
213 this study.

214
215

216 **12. What are my rights if I take part in this study?**
217

218 If you choose to participate in the study, you may discontinue participation at any time
219 without penalty or loss of benefits. By signing this form, you do not give up any personal
220 legal rights you may have as a participant in this study.
221

222 You will be provided with any new information that develops during the course of the
223 research that may affect your decision whether or not to continue participation in the
224 study.
225

226 You may refuse to participate in this study without penalty or loss of benefits to which
227 you are otherwise entitled.
228

229 An Institutional Review Board responsible for human subjects research at The Ohio State
230 University reviewed this research project and found it to be acceptable, according to
231 applicable state and federal regulations and University policies designed to protect the
232 rights and welfare of participants in research.
233
234

235 **13. Will my study-related information be kept confidential?**
236

237 Efforts will be made to keep your study-related information confidential. However, there
238 may be circumstances where this information must be released. For example, personal
239 information regarding your participation in this study may be disclosed if required by state
240 law.
241

242 Also, your records may be reviewed by the following groups (as applicable to the
243 research):

- 244 • Office for Human Research Protections or other federal, state, or international
245 regulatory agencies;
- 246 • U.S. Food and Drug Administration;
- 247 • The Ohio State University Institutional Review Board or Office of Responsible
248 Research Practices;
- 249 • The sponsor supporting the study, their agents or study monitors; and
- 250 • Your insurance company (if charges are billed to insurance).
251

252 A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as
253 required by U.S. law. This website will not include information that can identify you. At
254 most, the website will include a summary of the results. You can search the website at
255 any time.
256

257 We will work to make sure that no one sees your survey responses without approval. But,
258 because we are using the Internet, there is a chance that someone could access your online
259 responses without permission. In some cases, this information could be used to identify

260 you. Your data will be protected with a code to reduce the risk that other people can view
261 the responses.

262

263 **14. HIPAA AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR**
264 **RESEARCH PURPOSES**

265

266 **I. What information may be used and given to others?**

267

- 268 • Past and present medical records;
- 269 • Research records;
- 270 • Records about phone calls made as part of this research;
- 271 • Records about your study visits;
- 272 • Information that includes personal identifiers, such as your name, or a number
273 associated with you as an individual;

274

275 Information gathered for this research about:

276

HIV / AIDS

277

Hepatitis infection

278

Sexually transmitted diseases

279

Other reportable infectious diseases

280

Physical exams

281

Laboratory, x-ray, and other test results

282

Diaries and questionnaires

283

The diagnosis and treatment of a mental health condition

284

285 **II. Who may use and give out information about you?**

286

287 Researchers and study staff.

288

289 **III. Who might get this information?**

290

- 291 • The sponsor of this research. “Sponsor” means any persons or companies that are:
 - 292 • working for or with the sponsor; or
 - 293 • owned by the sponsor.
- 294 • Authorized Ohio State University staff not involved in the study may be aware that
295 you are participating in a research study and have access to your information;
- 296 • If this study is related to your medical care, your study-related information may be
297 placed in your permanent hospital, clinic or physician’s office record;
- 298 • Others: The U.S. Food and Drug Administration (FDA), Department of Health and
299 Human Services (DHHS) agencies, Governmental agencies in other countries,
300 Governmental agencies to whom certain diseases (reportable diseases) must be
301 reported, The Ohio State University units involved in managing and approving the
302 research study including the University Research Foundation and the Office of

303 Responsible Research Practices, and Western Institutional Review Board®
304 (WIRB®)
305

306 **IV. Your information may be given to:**
307

- 308 • The U.S. Food and Drug Administration (FDA), Department of Health and Human
309 Services (DHHS) agencies, and other federal and state entities;
- 310 • Governmental agencies in other countries;
- 311 • Governmental agencies to whom certain diseases (reportable diseases) must be
312 reported; and
- 313 • The Ohio State University units involved in managing and approving the research
314 study including the Office of Research and the Office of Responsible Research
315 Practices.

316
317 **V. Why will this information be used and/or given to others?**
318

- 319 • To do the research;
- 320 • To study the results; and
- 321 • To make sure that the research was done right.

322
323 If the results of this study are made public, information that identifies you will not be used.
324

325 **VI. When will my permission end?**
326

327 There is no date at which your permission ends. Your information will be used
328 indefinitely. This is because the information used and created during the study may be
329 analyzed for many years, and it is not possible to know when this will be complete.
330

331 **VII. May I withdraw or revoke (cancel) my permission?**
332

333 Yes. Your authorization will be good for the time period indicated above unless you
334 change your mind and revoke it in writing. You may withdraw or take away your
335 permission to use and disclose your health information at any time. You do this by
336 sending written notice to the researchers. If you withdraw your permission, you will not
337 be able to stay in this study. When you withdraw your permission, no new health
338 information identifying you will be gathered after that date. Information that has already
339 been gathered may still be used and given to others.
340

341 **VIII. What if I decide not to give permission to use and give out my health
342 information?**
343

344 Then you will not be able to be in this research study and receive research-related
345 treatment. However, if you are being treated as a patient here, you will still be able to
346 receive care.

347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380

IX. Is my health information protected after it has been given to others?

There is a risk that your information will be given to others without your permission. Any information that is shared may no longer be protected by federal privacy rules.

X. May I review or copy my information?

Signing this authorization also means that you may not be able to see or copy your study-related information until the study is completed.

15. Who can answer my questions about the study?

For questions, concerns, or complaints about the study, or if you feel you have been harmed as a result of study participation, you may contact:

Christopher Kaeding, MD at (614) 293-8813 (24 hours)

For questions related to your privacy rights under HIPAA or related to this research authorization, please contact HIPAA Privacy Officer, Suite E2140, 600 Ackerman Road, Columbus, OH 43201, 614-293-4477.

For questions about your rights as a participant in this study or to discuss other study-related concerns or complaints with someone who is not part of the research team, you may contact Ms. Sandra Meadows in the Office of Responsible Research Practices at 1-800-678-6251.

If you are injured as a result of participating in this study or for questions about a study-related injury, you may contact:

Christopher Kaeding, MD at (614) 293-8813 (24 hours)

381 **Signing the consent form**

382
383 I have read (or someone has read to me) this form and I am aware that I am being asked to
384 participate in a research study. I have had the opportunity to ask questions and have had them
385 answered to my satisfaction. I voluntarily agree to participate in this study.

386
387 I am not giving up any legal rights by signing this form. I will be given a copy of this
388 combined consent and HIPAA research authorization form.
389

_____	_____
Printed name of subject	Signature of subject
	_____ AM/PM
	Date and time
_____	_____
Printed name of person authorized to consent for subject (when applicable)	Signature of person authorized to consent for subject (when applicable)
	_____ AM/PM
_____	_____
Relationship to the subject	Date and time

390
391
392 **Investigator/Research Staff**

393
394
395 I have explained the research to the participant or his/her representative before requesting the
396 signature(s) above. There are no blanks in this document. A copy of this form has been given
397 to the participant or his/her representative.
398

_____	_____
Printed name of person obtaining consent	Signature of person obtaining consent
	_____ AM/PM
	Date and time

399 **Witness(es)** - *May be left blank if not required by the IRB*

_____	_____
Printed name of witness	Signature of witness
	_____ AM/PM
	Date and time
_____	_____
Printed name of witness	Signature of witness
	_____ AM/PM
	Date and time